Third time the charm for Alzheimer's drug?

Share this article:

Eli Lilly's experimental Alzheimer's treatment was ruled a failure in two earlier trials. But when investigators combined solanezumab's data from both tests, they discovered that cognitive declines were slowed by 34% among patients who started out with mild symptoms. Based on those results, solanezumab has been selected for a federally sponsored study for people who have not yet suffered significant memory loss. Brigham and Women's Hospital is helping coordinate the three-year investigation, which could cost up to $100 million."This is the first time investigators will test an amyloid-clearing drug in older individuals thought to be in the pre-symptomatic stage of Alzheimer's disease," the hospital announced. They are hoping the medication will reduce memory decline by 30%.

Share this article:

More in Products

Nurse technology contest seeks applications

Nurses who want to share the ways technology has led to a better student or patient outcome are invited to enter a contest that touts two $10,000 cash awards.

Accessory for swimming approved for cochlear implants

Accessory for swimming approved for cochlear implants ...

The Food and Drug Administration has approved the Aqua+ accessory, a waterproof, behind-the-ear product for cochlear implant recipients. The accessory allows Cochlear™ Nucleus® 5 and Nucleus 6 Implant recipients2 to ...

Non-Invasive Open Ventilation System approved

Non-Invasive Open Ventilation System approved

Breathe Technologies, which makes the Non-Invasive Open Ventilation (NIOV) System, said the Food and Drug Administration has granted the fifth 510(k) clearance for the product.